Belvedere Trading
HUMA icon

Belvedere Trading’s Humacyte HUMA Stock Holding History

Belvedere Trading’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,035
Closed -$52K – 530
2021
Q4 		$52K Buy
10,035
+1,364
+16% +$13.5K ﹤0.01% 356
2021
Q3 		$87K Buy
+8,671
New +$99.2K ﹤0.01% 369

Other funds holding HUMA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIA
Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return

Belvedere Trading's HUMA Position: Q1 2022 in Review

Belvedere Trading sold out of Humacyte (HUMA) in Q1 2022, closing a stake of 10,035 shares — an estimated $52K sold.

Belvedere Trading first reported a position in HUMA in Q3 2021 and held it in 2 quarters. The position peaked at $87K in Q3 2021. 70 funds tracked by Wall St. Rank hold HUMA as of Q1 2022.

  • Belvedere Trading reported no remaining Humacyte position as of Q1 2022 after selling out during the quarter.
  • Belvedere Trading sold 10,035 Humacyte shares in Q1 2022, an estimated $52K.
  • Belvedere Trading first reported a position in Humacyte in Q3 2021 and held it in 2 quarters.
  • Belvedere Trading's Humacyte position peaked at $87K in Q3 2021.
  • 70 funds tracked by Wall St. Rank held Humacyte as of Q1 2022.

Based on Belvedere Trading's 13F filing for Q1 2022, filed 20 Apr 2022.